FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1281-1282 September 21, 2006 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Strunk, R. C. PubMed Citation

To the Editor: Strunk and Bloomberg (June 22 issue)¹ discuss omalizumab for the treatment of asthma associated with high serum IgE levels. We provided care for a man who received omalizumab and in whom the Churg–Strauss syndrome subsequently developed.

Our patient was a 55-year-old man with a history of asthma who presented with acute onset of numbness and tingling in his extremities. A neurologic examination was notable for hyporeflexia. The patient had a purpuric rash on both lower extremities. A pulmonary examination was unremarkable. The white-cell count was 23.1x10³ per microliter with 47% eosinophils. Skin biopsy revealed a . . . [Full Text of this Article]

This article has been cited by other articles:

• Wechsler, M. E., Wong, D. A., Miller, M. K., Lawrence-Miyasaki, L. (2009). Churg-Strauss Syndrome in Patients Treated With Omalizumab. Chest 136: 507-518 [Abstract] [Full Text]  
• Pelaia, G., Renda, T., Romeo, P., Busceti, M. T., Maselli, R. (2008). Review: Omalizumab in the treatment of severe asthma: efficacy and current problems. Ther Adv Respir Dis 2: 409-421 [Abstract]